MARKET

ENTA

ENTA

Enanta Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

50.71
+0.73
+1.46%
After Hours: 50.71 0 0.00% 17:01 04/03 EDT
OPEN
49.87
PREV CLOSE
49.98
HIGH
51.00
LOW
48.33
VOLUME
148.23K
TURNOVER
--
52 WEEK HIGH
101.27
52 WEEK LOW
38.40
MARKET CAP
1.01B
P/E (TTM)
31.35
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 7 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ENTA stock price target is 83.40 with a high estimate of 130.00 and a low estimate of 47.00.

EPS

ENTA News

More
  • TherapeuticsMD Suspends Guidance, And Other News: The Good, Bad And Ugly Of Biopharma
  • Seeking Alpha - Article · 03/27 15:03
  • Enanta Provides Update on Clinical Development Activities During COVID-19 Pandemic
  • Business Wire · 03/26 21:05
  • Enanta Pharma suspends recruitment in trials amid Covid-19
  • Seeking Alpha - Article · 03/26 20:53
  • Selloff creating bargains in healthcare - Baird
  • Seeking Alpha - Article · 03/25 17:54

Industry

Biotechnology & Medical Research
-0.50%
Pharmaceuticals & Medical Research
-0.22%

Hot Stocks

Symbol
Price
%Change

About ENTA

Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). It has discovered novel protease inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). These protease inhibitors, developed through its collaboration with AbbVie Inc. (AbbVie), include paritaprevir and glecaprevir (ABT-493). Its product candidates also include EDP-305, which is a farnesoid X receptor (FXR) agonist product candidate for NASH and PBC, and EDP-938, which is a clinical candidate for RSV.
More

Webull offers kinds of Enanta Pharmaceuticals Inc stock information, including NASDAQ:ENTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENTA stock news, and many more online research tools to help you make informed decisions.